A Phase 1/2, Open-Label Safety, Pharmacokinetic and Efficacy Study of TAS4464 in Patients With Multiple Myeloma or Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs TAS 4464 (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiho Oncology
- 07 Mar 2018 Status changed from recruiting to discontinued.
- 01 May 2017 Status changed from not yet recruiting to recruiting.
- 08 Dec 2016 New trial record